-
1
-
-
0036275356
-
Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin [mTOR]-dependent signaling
-
Humar R, Kiefer FN, Berns H, et al. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin [mTOR]-dependent signaling. FASEB J 2002;16:771-80
-
(2002)
FASEB J
, vol.16
, pp. 771-780
-
-
Humar, R.1
Kiefer, F.N.2
Berns, H.3
-
2
-
-
63749097287
-
Optimal targeting of the mTORC1 kinase in human cancer
-
Lane HA, Breuleux M. Optimal targeting of the mTORC1 kinase in human cancer. Curr Opin Cell Biol 2009;21: 219-29
-
(2009)
Curr Opin Cell Biol
, vol.21
, pp. 219-229
-
-
Lane, H.A.1
Breuleux, M.2
-
3
-
-
52049125970
-
Efficacy of RAD001 [everolimus] and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: Results of a phase II study
-
Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 [everolimus] and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26(26):4311-18
-
(2008)
J Clin Oncol
, vol.26
, Issue.26
, pp. 4311-4318
-
-
Yao, J.C.1
Phan, A.T.2
Chang, D.Z.3
-
4
-
-
84879899632
-
Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: Observations from a phase III clinical trial
-
Peterson ME. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Support Care Cancer 2013; 21(8):2341-9
-
(2013)
Support Care Cancer
, vol.21
, Issue.8
, pp. 2341-2349
-
-
Peterson, M.E.1
-
5
-
-
84906976984
-
Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors
-
Panzuto F, Rinzivillo M, Fazio N, et al. Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors. Oncologist 2014;19(9):966-74
-
(2014)
Oncologist
, vol.19
, Issue.9
, pp. 966-974
-
-
Panzuto, F.1
Rinzivillo, M.2
Fazio, N.3
-
6
-
-
84922641162
-
Adverse event management of mTOR inhibitors during treatment of hormone receptor-positive advanced breast cancer: Considerations for oncologists
-
Yardley DA. Adverse event management of mTOR inhibitors during treatment of hormone receptor-positive advanced breast cancer: considerations for oncologists. Clin Breast Cancer 2014;14(5):297-308
-
(2014)
Clin Breast Cancer
, vol.14
, Issue.5
, pp. 297-308
-
-
Yardley, D.A.1
-
8
-
-
84925548115
-
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
-
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62(10):1006-12
-
(2009)
J Clin Epidemiol
, vol.62
, Issue.10
, pp. 1006-1012
-
-
Moher, D.1
Liberati, A.2
Tetzlaff, J.3
-
10
-
-
0022992740
-
Meta-analysis in clinical trials
-
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3): 177-88
-
(1986)
Control Clin Trials
, vol.7
, Issue.3
, pp. 177-188
-
-
Dersimonian, R.1
Laird, N.2
-
11
-
-
84925503797
-
Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): Biological rationale and critical review of published data
-
Abdel-Rahman O, Fouad M. Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data. Tumor Biol 2015;36(2):467-78
-
(2015)
Tumor Biol
, vol.36
, Issue.2
, pp. 467-478
-
-
Abdel-Rahman, O.1
Fouad, M.2
-
12
-
-
84888395367
-
Everolimus as treatment for breast cancer patients with bone metastases only: Results of the phase II RADAR study
-
Maass N, Harbeck N, Mundhenke C, et al. Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. J Cancer Res Clin Oncol 2013;139(12):2047-56
-
(2013)
J Cancer Res Clin Oncol
, vol.139
, Issue.12
, pp. 2047-2056
-
-
Maass, N.1
Harbeck, N.2
Mundhenke, C.3
-
13
-
-
77956227464
-
Phase 3 trial of Everolimus for metastatic renal cell carcinoma : Final results and analysis of prognostic factors
-
Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of Everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010; 116(18):4256-65
-
(2010)
Cancer
, vol.116
, Issue.18
, pp. 4256-4265
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
-
14
-
-
84911899123
-
Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; A systematic review and meta-analysis
-
Abdel-Rahman O. Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis. Expert Rev Anti Ther 2014;14(12):1529-36
-
(2014)
Expert Rev Anti Ther
, vol.14
, Issue.12
, pp. 1529-1536
-
-
Abdel-Rahman, O.1
-
15
-
-
84921384735
-
Everolimus for patients with metastatic renal cell carcinoma (mRCC) refractory to anti-VEGF therapy: Preliminary results of a pooled analysis of noninterventional studies
-
Albiges L, Bergmann L, Eymard JC, et al. Everolimus for patients with metastatic renal cell carcinoma (mRCC) refractory to anti-VEGF therapy: preliminary results of a pooled analysis of noninterventional studies. J Clin Oncol 2013;31(6
-
(2013)
J Clin Oncol
, vol.31
, Issue.6
-
-
Albiges, L.1
Bergmann, L.2
Eymard, J.C.3
-
16
-
-
80053377953
-
Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: Insights into compliance issues
-
Ferte C, Paci A, Zizi M, et al. Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur J Cancer 2011; 47(15):2249-55
-
(2011)
Eur J Cancer
, vol.47
, Issue.15
, pp. 2249-2255
-
-
Ferte, C.1
Paci, A.2
Zizi, M.3
-
17
-
-
74549192779
-
Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients
-
Sonis S, Treister N, Chawla S, et al. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 2010;116(1):210-15
-
(2010)
Cancer
, vol.116
, Issue.1
, pp. 210-215
-
-
Sonis, S.1
Treister, N.2
Chawla, S.3
-
18
-
-
84925649982
-
Risk of fatigue in patients with solid tumors treated with everolimus temsirolimus or ridaforolimus: A comparative meta-analysis
-
Abdel-Rahman O, Fouad M. Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis. Expert Rev Anti Ther 2015;15(4):477-86
-
(2015)
Expert Rev Anti Ther
, vol.15
, Issue.4
, pp. 477-486
-
-
Abdel-Rahman, O.1
Fouad, M.2
-
19
-
-
84921061457
-
Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: A meta-analysis
-
Abdel-Rahman O, Fouad M. Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis. Future Oncol 2015;11(1):79-90
-
(2015)
Future Oncol
, vol.11
, Issue.1
, pp. 79-90
-
-
Abdel-Rahman, O.1
Fouad, M.2
-
20
-
-
84878217451
-
Practical management of everolimus-related toxicities in patients with advanced solid tumors
-
Gruenwald V, Weikert S, Pavel ME, et al. Practical management of everolimus-related toxicities in patients with advanced solid tumors. Onkologie 2013;36(5):295-302
-
(2013)
Onkologie
, vol.36
, Issue.5
, pp. 295-302
-
-
Gruenwald, V.1
Weikert, S.2
Pavel, M.E.3
-
21
-
-
84880199344
-
Oral ulcers in patients with advanced breast cancer receiving everolimus: A case series report on clinical presentation and management
-
Nicolatou-Galitis O, Nikolaidi A, Athanassiadis I, et al. Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; 116(2):e110-16
-
(2013)
Oral Surg Oral Med Oral Pathol Oral Radiol
, vol.116
, Issue.2
, pp. e110-e116
-
-
Nicolatou-Galitis, O.1
Nikolaidi, A.2
Athanassiadis, I.3
-
22
-
-
80053959068
-
Clinical presentation and management of mTOR inhibitor-associated stomatitis
-
De Oliveira MA, Martinse Martins F, Wang Q, et al. Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol 2011;47(10): 998-1003
-
(2011)
Oral Oncol
, vol.47
, Issue.10
, pp. 998-1003
-
-
De Oliveira, M.A.1
Martinse Martins, F.2
Wang, Q.3
-
23
-
-
84897102034
-
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: Insights from BOLERO-2
-
Rugo HS, Pritchard KI, Gnant M, et al. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol 2014;25(4):808-15
-
(2014)
Ann Oncol
, vol.25
, Issue.4
, pp. 808-815
-
-
Rugo, H.S.1
Pritchard, K.I.2
Gnant, M.3
-
24
-
-
84901648923
-
Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: The LARCID trial
-
Hoff PM, Saragiotto DF, Barrios CH, et al. Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: The LARCID trial. J Clin Oncol 2014; 32(10):1006-11
-
(2014)
J Clin Oncol
, vol.32
, Issue.10
, pp. 1006-1011
-
-
Hoff, P.M.1
Saragiotto, D.F.2
Barrios, C.H.3
-
25
-
-
84878396894
-
Neoadjuvant chemotherapy with paclitaxel and Everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide [EC] ± bevacizumab-results of the randomised GeparQuinto study [GBG 44]
-
Huober J, Fasching PA, Hanusch C, et al. Neoadjuvant chemotherapy with paclitaxel and Everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide [EC] ± bevacizumab-results of the randomised GeparQuinto study [GBG 44]. Eur J Cancer 2013; 49(10):2284-93
-
(2013)
Eur J Cancer
, vol.49
, Issue.10
, pp. 2284-2293
-
-
Huober, J.1
Fasching, P.A.2
Hanusch, C.3
-
26
-
-
84872088946
-
Efficacy and safety of Everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex [EXIST-1]: A multicentre randomised placebo-controlled phase 3 trial
-
Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of Everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex [EXIST-1]: a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013;381(9861):125-32
-
(2013)
Lancet
, vol.381
, Issue.9861
, pp. 125-132
-
-
Franz, D.N.1
Belousova, E.2
Sparagana, S.3
-
27
-
-
84899630091
-
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial
-
Rini BI, Bellmunt J, Clancy J, et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 2014;32(8):752-9
-
(2014)
J Clin Oncol
, vol.32
, Issue.8
, pp. 752-759
-
-
Rini, B.I.1
Bellmunt, J.2
Clancy, J.3
-
28
-
-
84874746597
-
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis [EXIST-2]: A multicentre randomised double-blind placebo-controlled trial
-
Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis [EXIST-2]: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013;381(9869):817-24
-
(2013)
Lancet
, vol.381
, Issue.9869
, pp. 817-824
-
-
Bissler, J.J.1
Kingswood, J.C.2
Radzikowska, E.3
-
29
-
-
84864558874
-
Randomized phase II trial of Everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study
-
Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of Everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012;30(22):2718-24.
-
(2012)
J Clin Oncol
, vol.30
, Issue.22
, pp. 2718-2724
-
-
Bachelot, T.1
Bourgier, C.2
Cropet, C.3
-
30
-
-
84863078767
-
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
-
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366(6):520-9.
-
(2012)
N Engl J Med
, vol.366
, Issue.6
, pp. 520-529
-
-
Baselga, J.1
Campone, M.2
Piccart, M.3
-
31
-
-
84872518645
-
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer
-
Wolff AC, Lazar AA, Bondarenko I, et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013;31(2):195-202
-
(2013)
J Clin Oncol
, vol.31
, Issue.2
, pp. 195-202
-
-
Wolff, A.C.1
Lazar, A.A.2
Bondarenko, I.3
-
32
-
-
84891371392
-
Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study
-
Ohtsu A, Ajani JA, Bai YX, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 2013;31(31):3935-43
-
(2013)
J Clin Oncol
, vol.31
, Issue.31
, pp. 3935-3943
-
-
Ohtsu, A.1
Ajani, J.A.2
Bai, Y.X.3
-
33
-
-
84899992665
-
Everolimus for women with trastuzumab-resistant HER2-positive advanced breast cancer [BOLERO-3]: A randomised double-blind placebo-controlled phase 3 trial
-
Andre F, O'Regan R, Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer [BOLERO-3]: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014;15(6):580-91
-
(2014)
Lancet Oncol
, vol.15
, Issue.6
, pp. 580-591
-
-
Andre, F.1
O'Regan, R.2
Ozguroglu, M.3
-
34
-
-
84903593280
-
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: The EVOLVE-1 randomized clinical trial
-
Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: The EVOLVE-1 randomized clinical trial. JAMA 2014;312(1):57-67
-
(2014)
JAMA
, vol.312
, Issue.1
, pp. 57-67
-
-
Zhu, A.X.1
Kudo, M.2
Assenat, E.3
-
35
-
-
79851500081
-
Everolimus for advanced pancreatic neuroendocrine tumors
-
Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):514-23
-
(2011)
N Engl J Med
, vol.364
, Issue.6
, pp. 514-523
-
-
Yao, J.C.1
Shah, M.H.2
Ito, T.3
-
36
-
-
68949102180
-
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
-
Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27(23):3822-9
-
(2009)
J Clin Oncol
, vol.27
, Issue.23
, pp. 3822-3829
-
-
Hess, G.1
Herbrecht, R.2
Romaguera, J.3
-
37
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81
-
(2007)
N Engl J Med
, vol.356
, Issue.22
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
-
38
-
-
84883063380
-
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy
-
Demetri GD, Chawla SP, Ray-Coquard I, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol 2013;31(19): 2485-92
-
(2013)
J Clin Oncol
, vol.31
, Issue.19
, pp. 2485-2492
-
-
Demetri, G.D.1
Chawla, S.P.2
Ray-Coquard, I.3
-
42
-
-
66849136781
-
Phase II randomized study of neoadjuvant Everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer
-
Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant Everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27(16):2630-7
-
(2009)
J Clin Oncol
, vol.27
, Issue.16
, pp. 2630-2637
-
-
Baselga, J.1
Semiglazov, V.2
Van Dam, P.3
-
43
-
-
83255167036
-
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome [RADIANT-2]: A randomised, placebo-controlled, phase III study
-
Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome [RADIANT-2]: a randomised, placebo-controlled, phase III study. Lancet 2011;378(9808):2005-12
-
(2011)
Lancet
, vol.378
, Issue.9808
, pp. 2005-2012
-
-
Pavel, M.E.1
Hainsworth, J.D.2
Baudin, E.3
|